Vyne Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vyne Therapeutics Inc 's ROA in the second quarter of 2026?
Vyne Therapeutics Inc recorded a cumulative net loss of $-12 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -39.68%.

However, within the Healthcare sector 479 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3873, from total ROA ranking in the first quarter of 2026 at 4620.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-57.03 %	-61.27 %	-59.07 %	-46.95 %	-39.02 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-12	-18	-26	-39	-42
Return On Assets (TTM)	-39.68 %	-46.09 %	-53.67 %	-64.29 %	-60.47 %
VYNE's Total Ranking	# 3873	# 4620	#	# 4217	# 4258
Total Assets (TTM) in million	24	26	30	44	55
Seq. Total Assets Change	-8.62 %	-14.04 %	-32.28 %	-19.22 %	-17.65 %
Seq. Net Income Change	-	-	-	-	-

VYNE's 5 Years Annual ROA >> Back to VYNE Management Effectiveness >> Compare VYNE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 190
Sector	# 480
Overall	# 3744

Return On Assets Statistics
High	Average	Low
207.44 %	-4.99 %	-107.14 %
(Dec 31 2020)		(Sep 30 2023)

Financial Statements
Vyne Therapeutics Inc 's Assets	$ 24 million	VYNE's Balance sheet
Vyne Therapeutics Inc 's Income	$ -3 million	Quarterly VYNE's Income Statement
VYNE's Income by Division		See VYNE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-54.95 %	-31.46 %	139.16 %	-39.21 %	-27.76 %
Total Assets in million	30	67	97	41	67
Y / Y Net Income Change	-	-	-	-	-71.31 %
Net Income in million	-26	-40	-28	-23	73
Annual Return On Assets	-87.98 %	-59.62 %	-29.19 %	-56.95 %	109.37 %

VYNE's 5 Years Annual ROA >> Back to VYNE Management Effectiveness >> Compare VYNE ROA to its Competitors

More Return On Assets Ratios
VYNE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VYNE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VYNE's Competitors
Subscribers only: Roa for Vyne Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for VYNE's Customers

You may also want to know
VYNE's Roi	VYNE's Inventory Turnover Ratio	VYNE's Growth Rates	VYNE's Dividend Comparisons
	VYNE's Profitability Ratios	VYNE's Asset Turnover Ratio	VYNE's Dividend Growth
VYNE's Roe	VYNE's Valuation Ratios	VYNE's Financial Strength Ratios	VYNE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-02T20:18:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.